Takeaway

• A phase 2a basket study found that the combination of pertuzumab and trastuzumab produced a 23% response rate in HER2 ⁺ metastatic biliary cancer.

Why this matters

• There are few available treatments for this population.

Study design

• Nonrandomized, multicenter, open-label, phase 2a basket study (MyPathway, n=39).
• Funding: F. Hoffmann-La...